The first overall survival data for HER-Vaxx (IMU-131) were published in the preliminary HERIZON study results, demonstrating overall survival of 13.9 months with HER-Vaxx with chemotherapy vs. 8.3 months for chemotherapy alone, in the second-line setting for advanced HER2+ GC and GEJC [73]. Here, ERBB2 is linked to gastric cancer.